References
- Gaston RS, Giltin MH. Psychological and financial aspects of kidney transplantation. In: Handbook of Kidney Transplantation. Danovitch GM (Ed.). Lippincott Williams and Wilkins, PA, USA (2005).
- Gordon EJ, Prohaska TR, Seghal AR. The financial impact of immunosuppressant expenses on new kidney transplant recipients. Clin. Transplant.6, 738–748 (2008).
- Page TF, Woodward RS. Cost of lifetime immunosuppression coverage for kidney transplant recipients. Healthcare Financ. Rev.30(2), 95–104 (2009).
- Yen EF, Hardinger K, Brennan DC et al. Cost–effectiveness of extending medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am. J. Transplant.4, 1703–1708 (2004).
- Danovitch GM. Immunosuppressive medicatons and protocols for kidney transplantation. In: Handbook of Kidney Transplantation. Danovitch GM (Ed.). Lippincott Williams and Wilkins, PA, USA (2005).
- Morton RL, Howard K, Webster AC, Wong G, Craig JC. Cost–effectiveness of induction immunosuppression in kidney transplantation. Nephrol. Dial. Transplant.24, 2258–2269 (2009).
- Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation49, 372–377 (1990).
- Shoskes DA, Avelino L, Barba L, Sender M. Patient death or renal graft loss within 3 years of transplantation in a county hospital: importance of poor initial graft function. Clin. Transplant.11, 618–622 (1997).
- Hong JH, Sumrani N, Delaney V, Dibenedetto A, Butt KM. Cases of late renal allograft failure in the ciclosporine era. Nephron62, 272–279 (1992).
- Gaston RS, Hudson SL, Ward M, Jones P, Macon R. Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant. Proc.31, S21–S23 (1999).
- Goodman WG, Danovitch GM. Options for patients with kidney failure. In: Handbook of Kidney Transplantation. Danovitch GM (Ed.). Lippincott Williams and Wilkins, PA, USA (2005).
- Feenberg D, Coutts E. An introduction to the TAXSIM model. JPAM12(1), 189–194 (1993).
- Woodward RS, Schnitzler MA, Lowell JA, Spitznagel EL. Effect of extending coverage of immunosuppressive medications by medicare on the survival of cadaveric renal transplants. Am. J. Transplant.1, 69–73 (2001).
- Woodward RS, Page TF, Soares R, Schnitzler MA, Lentine KL, Brennan DC. Income-related disparities in kidney transplant graft failures are eliminated by medicare’s immunosuppression coverage. Am. J. Transplant.8, 2636–2646 (2008).
- Piketty T, Emmanuel S. Income inequality in the United States, 1913–1998. Q. J. Econ.118(1), 1–39 (2003) (series updat, 2008).
- Kasiske BL, Cohen D, Lucey MR, Neylan JF. Payment for immunosuppression after organ transplantation. J. Am. Med. Assoc.283(18), 24445–24450 (2000).
- Gordon EJ. Article: sumposium: precious commodities: the supply & demand of body parts: the ethics of medicare policy. De Paul Law Rev.55, 1045 (2006).
- Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J. Risk Uncertain.27(1), 5–76 (2003).
- Ashenfelter Orley. Measuring the value of a statistical life: problems and prospectus. IZA27(1), 5–76 (2006).
- Neil N, Guest S, Wong L et al. The financial implications for Medicare of greater use of peritoneal dialysis. Clin. Therapeutics31(4), 880–888 (2009).
Websites
- USRDS 2008 Annual Data Report. www.usrds.org/adr_2008.htm (Accessed 19 June 09)
- United States Census Bureau. www.census.gov/hhes/www/income/income.html (Accessed 19 June 2009)
- National Bureau of Economic Research Taxsim Calculator. www.nber.org/~taxsim (Accessed 20 June 2009)